Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: LANCE B who wrote (21663)	2/23/2000 10:01:00 AM
From: hoffy	Respond to of 25711

New genomics play. Low priced. MFIC. very Low float. News out today. Looks great for a run. Company has real revenues too. ================================================================= Wednesday February 23, 8:12 am Eastern Time Company Press Release MFIC Corporation Systems Enable Genomics - Its Technology Critical to Leading Biotechnology Companies NEWTON, Mass.--(BUSINESS WIRE)--Feb. 23, 2000--(OTCBB:MFIC - news)--Genomics research and materials preparation activities require systems to disrupt cells as part of their purification/analysis process. Recombinant proteins are widely used as key pharmaceuticals, including insulin, interferon, infectious disease vaccines (such as hepatitis-B) and human growth hormone. MFIC's proprietary cell disruption systems and formulation equipment are critical components in the development and manufacturing efforts of Genomics enterprises, both for recombinant proteins and modified gene/vector products. Scientists and engineers involved in isolating genetically-produced proteins use a variety of cells to produce these proteins, including bacteria, yeast, mammalian cells and insect cells. MFIC's Microfluidizer® materials processor equipment is the industry standard for an efficient, clean, high yield process in which protein-bearing components are separated from the disrupted cells. After cells are grown in cultures, the Microfluidizer processing system is employed to disrupt the cell walls and allow separation of the desired protein-rich cellular fluids. Further purification is facilitated through minimal contamination by membrane proteins and grinding media contaminants, often a problem when utilizing alternative processes. Microfluidizer processor systems are scaleable, and production systems are used to create pharmaceutical formulations suitable for selected delivery routes, such as injectables, parenterals, vaccines, and liposomal encapsulation for injection or topical administration. The new agents incorporating modified genes and vectors, such as adenoviruses, are also prepared with Microfluidizer materials processing systems. Michael A. Lento, President of MFIC, stated, ''We are gratified to see our technology widely used by our customers to implement advanced life-saving therapies based on new, genomically-derived agents, as well as in formulations which enable delivery options for protein-based drugs.'' Irwin Gruverman, CEO and Chairman of MFIC, added, ''MFIC has served the worldwide biotechnology community since 1982. We are pleased to receive recognition in the Genomics area as a critical enabling technology.''